Bladder Cancer - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 801 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H1 2017, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 51, 43, 1, 52 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 11 and 2 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 7
Bladder Cancer - Overview 8
Bladder Cancer - Therapeutics Development 9
Bladder Cancer - Therapeutics Assessment 32
Bladder Cancer - Companies Involved in Therapeutics Development 50
Bladder Cancer - Drug Profiles 108
Bladder Cancer - Dormant Projects 759
Bladder Cancer - Discontinued Products 765
Bladder Cancer - Product Development Milestones 767
Appendix 781

List of Tables

Number of Products under Development for Bladder Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Bladder Cancer - Pipeline by 4SC AG, H1 2017
Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
Bladder Cancer - Pipeline by ADC Therapeutics Sarl, H1 2017
Bladder Cancer - Pipeline by Agenus Inc, H1 2017
Bladder Cancer - Pipeline by Altor BioScience Corp, H1 2017
Bladder Cancer - Pipeline by AndroScience Corp, H1 2017
Bladder Cancer - Pipeline by ANP Technologies Inc, H1 2017
Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2017
Bladder Cancer - Pipeline by Archivel Farma SL, H1 2017
Bladder Cancer - Pipeline by Argos Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Arno Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Array BioPharma Inc, H1 2017
Bladder Cancer - Pipeline by Asana BioSciences LLC, H1 2017
Bladder Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2017
Bladder Cancer - Pipeline by Astellas Pharma Inc, H1 2017
Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by AstraZeneca Plc, H1 2017
Bladder Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
Bladder Cancer - Pipeline by Bayer AG, H1 2017
Bladder Cancer - Pipeline by BioCancell Ltd, H1 2017
Bladder Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
Bladder Cancer - Pipeline by Bioncotech Therapeutics SL, H1 2017
Bladder Cancer - Pipeline by Biotest AG, H1 2017
Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Bladder Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Bladder Cancer - Pipeline by Celgene Corp, H1 2017
Bladder Cancer - Pipeline by Cellceutix Corp, H1 2017
Bladder Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Celprogen Inc, H1 2017
Bladder Cancer - Pipeline by Celsion Corp, H1 2017
Bladder Cancer - Pipeline by Celyad SA, H1 2017
Bladder Cancer - Pipeline by Cold Genesys Inc, H1 2017
Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Eisai Co Ltd, H1 2017
Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Eli Lilly and Company, H1 2017
Bladder Cancer - Pipeline by Elsalys Biotech SAS, H1 2017
Bladder Cancer - Pipeline by EpiThany Inc, H1 2017
Bladder Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by Exelixis Inc, H1 2017
Bladder Cancer - Pipeline by Exicure Inc, H1 2017
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Bladder Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by For-Robin Inc, H1 2017
Bladder Cancer - Pipeline by Gene Signal International SA, H1 2017
Bladder Cancer - Pipeline by Genmab A/S, H1 2017
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
Bladder Cancer - Pipeline by H3 Biomedicine Inc, H1 2017
Bladder Cancer - Pipeline by Hamlet Pharma AB, H1 2017
Bladder Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Bladder Cancer - Pipeline by HitGen LTD, H1 2017
Bladder Cancer - Pipeline by Horizon Pharma Plc, H1 2017
Bladder Cancer - Pipeline by Idera Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by Immunocore Ltd, H1 2017
Bladder Cancer - Pipeline by Immunomedics Inc, H1 2017
Bladder Cancer - Pipeline by Immupharma Plc, H1 2017
Bladder Cancer - Pipeline by Incanthera Ltd, H1 2017
Bladder Cancer - Pipeline by Incyte Corp, H1 2017
Bladder Cancer - Pipeline by InteRNA Technologies BV, H1 2017
Bladder Cancer - Pipeline by Johnson & Johnson, H1 2017
Bladder Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2017
Bladder Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc, H1 2017
Bladder Cancer - Pipeline by MacroGenics Inc, H1 2017
Bladder Cancer - Pipeline by Marina Biotech Inc, H1 2017
Bladder Cancer - Pipeline by MaxiVAX SA, H1 2017
Bladder Cancer - Pipeline by Meabco A/S, H1 2017
Bladder Cancer - Pipeline by Medicenna Therapeutics Corp, H1 2017
Bladder Cancer - Pipeline by MedImmune LLC, H1 2017
Bladder Cancer - Pipeline by Merck & Co Inc, H1 2017
Bladder Cancer - Pipeline by Merck KGaA, H1 2017
Bladder Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Moleculin Biotech Inc, H1 2017
Bladder Cancer - Pipeline by MTG Biotherapeutics Inc, H1 2017
Bladder Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017
Bladder Cancer - Pipeline by Nektar Therapeutics, H1 2017
Bladder Cancer - Pipeline by Omeros Corp, H1 2017
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by OncoTherapy Science Inc, H1 2017
Bladder Cancer - Pipeline by Oncovir Inc, H1 2017
Bladder Cancer - Pipeline by Optimum Therapeutics LLC, H1 2017
Bladder Cancer - Pipeline by Pfizer Inc, H1 2017
Bladder Cancer - Pipeline by Pharma Mar SA, H1 2017
Bladder Cancer - Pipeline by Philogen SpA, H1 2017
Bladder Cancer - Pipeline by Plexxikon Inc, H1 2017
Bladder Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by Provecs Medical GmbH, H1 2017
Bladder Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by PsiOxus Therapeutics Ltd, H1 2017
Bladder Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by Samyang Biopharmaceuticals Corp, H1 2017
Bladder Cancer - Pipeline by Sanofi, H1 2017
Bladder Cancer - Pipeline by Sareum Holdings Plc, H1 2017
Bladder Cancer - Pipeline by Shionogi & Co Ltd, H1 2017
Bladder Cancer - Pipeline by Sierra Oncology Inc, H1 2017
Bladder Cancer - Pipeline by Sillajen Biotherapeutics, H1 2017
Bladder Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by Stemline Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Bladder Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Bladder Cancer - Pipeline by Taris Biomedical LLC, H1 2017
Bladder Cancer - Pipeline by Theralase Technologies Inc, H1 2017
Bladder Cancer - Pipeline by Theravectys SA, H1 2017
Bladder Cancer - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
Bladder Cancer - Pipeline by Transgene SA, H1 2017
Bladder Cancer - Pipeline by UroGen Pharmaceuticals Ltd, H1 2017
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H1 2017
Bladder Cancer - Pipeline by Vault Pharma Inc, H1 2017
Bladder Cancer - Pipeline by Vaxeal Holding SA, H1 2017
Bladder Cancer - Pipeline by Vaxiion Therapeutics Inc, H1 2017
Bladder Cancer - Pipeline by Viralytics Ltd, H1 2017
Bladder Cancer - Dormant Projects, H1 2017
Bladder Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Bladder Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
Bladder Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
Bladder Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
Bladder Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
Bladder Cancer - Discontinued Products, H1 2017
Bladder Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017